Cabio Biotech Wuhan Stock Current Valuation
| 688089 Stock | 18.03 0.06 0.33% |
Valuation analysis of Cabio Biotech Wuhan helps investors to measure Cabio Biotech's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Cabio Biotech's Cash is projected to increase significantly based on the last few years of reporting. The current year's Total Cash From Operating Activities is expected to grow to about 123.2 M, whereas Change In Cash is projected to grow to (214.6 M). Fundamental drivers impacting Cabio Biotech's valuation include:
Price Book 1.9944 | Enterprise Value 2.9 B | Enterprise Value Ebitda 22.4908 | Price Sales 6.039 | Trailing PE 26.7059 |
Overvalued
Today
Please note that Cabio Biotech's price fluctuation is not too volatile at this time. Calculation of the real value of Cabio Biotech Wuhan is based on 3 months time horizon. Increasing Cabio Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cabio Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cabio Stock. However, Cabio Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 18.03 | Real 16.87 | Hype 18.04 | Naive 17.48 |
The real value of Cabio Stock, also known as its intrinsic value, is the underlying worth of Cabio Biotech Wuhan Company, which is reflected in its stock price. It is based on Cabio Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cabio Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cabio Biotech Wuhan helps investors to forecast how Cabio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cabio Biotech more accurately as focusing exclusively on Cabio Biotech's fundamentals will not take into account other important factors: Cabio Biotech Wuhan Company Current Valuation Analysis
Cabio Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cabio Biotech Current Valuation | 2.9 B |
Most of Cabio Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cabio Biotech Wuhan is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cabio Biotech Wuhan has a Current Valuation of 2.9 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all China stocks is notably lower than that of the firm.
Cabio Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cabio Biotech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cabio Biotech could also be used in its relative valuation, which is a method of valuing Cabio Biotech by comparing valuation metrics of similar companies.Cabio Biotech is currently under evaluation in current valuation category among its peers.
Cabio Fundamentals
| Return On Equity | 0.0733 | ||||
| Return On Asset | 0.0383 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 2.9 B | ||||
| Shares Outstanding | 168.31 M | ||||
| Shares Owned By Insiders | 50.75 % | ||||
| Shares Owned By Institutions | 4.86 % | ||||
| Price To Book | 1.99 X | ||||
| Price To Sales | 6.04 X | ||||
| Revenue | 443.8 M | ||||
| Gross Profit | 179.62 M | ||||
| EBITDA | 160.2 M | ||||
| Net Income | 91.37 M | ||||
| Total Debt | 12.1 M | ||||
| Book Value Per Share | 9.07 X | ||||
| Cash Flow From Operations | 68.89 M | ||||
| Earnings Per Share | 0.68 X | ||||
| Target Price | 17.0 | ||||
| Number Of Employees | 508 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 3.06 B | ||||
| Total Asset | 1.61 B | ||||
| Retained Earnings | 421.34 M | ||||
| Working Capital | 596.35 M | ||||
| Net Asset | 1.61 B | ||||
| Last Dividend Paid | 0.2 |
About Cabio Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cabio Biotech Wuhan's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cabio Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cabio Biotech Wuhan based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Cabio Stock
Cabio Biotech financial ratios help investors to determine whether Cabio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cabio with respect to the benefits of owning Cabio Biotech security.